Twist Bioscience Enhances Genes Product Offering with Longer Genes and Offers Access to Its Application Programming Interface
08 January 2019 - 12:00AM
Business Wire
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling
customers to succeed through its offering of high-quality synthetic
DNA, today announced it has expanded its product portfolio to offer
genes up to five kilobases (5kb) in length at industry-leading
pricing. In addition, Twist is making its Application Programming
Interface (Twist API or TAPI) available for all customers ordering
genes.
“We are committed to continuously improving and expanding our
product lines to serve more and more of our customers’ needs,” said
Emily M. Leproust, Ph.D., CEO and co-founder of Twist. “For the
last year, we have been supplying genes up to 5kb to Ginkgo
Bioworks, and we are confident in our ability to precisely
manufacture scalable quantities of these genes efficiently and
clonal perfect. By offering long genes at the disruptive price of
$0.15 per base pair with a turnaround time between 15 and 25 days,
we are continuing our efforts to increase our market share by
converting DNA makers into DNA buyers.”
Twist Application Programming Interface (TAPI) Now Available
for Gene Ordering
In addition to expanding its gene offering in length, Twist also
announced the availability of the Twist Application Programming
Interface (TAPI) for ordering synthetic genes, oligo pools and gene
fragments. TAPI allows customers to integrate their internal
software systems seamlessly with Twist’s design and business
systems. Importantly, TAPI offers the functionality of the Twist
online ordering portal with sequence synthesis analysis, codon
optimization, download of plate maps and a comprehensive order
tracking process from order placed to shipment received. These
features can save time and resources for customers.
“Once available only to our largest customers, we have opened up
our TAPI for all customers interested in designing and building
genes and their pathways in one step, while at the same time
transferring data directly and securely,” continued Dr.
Leproust.
About Clonal Perfect Synthetic Genes
Applying its proprietary DNA synthesis technology, Twist
manufactures strands of DNA up to five kilobases (5kb) in length.
Customers order synthetic genes to conduct a wide range of
research, including product development for the healthcare,
agricultural, and industrial chemical industries as well as a
multitude of applications within academic research. Virtually all
research and development requires trial and error, and institutions
require many variations of genes to find the DNA sequence that
achieves their objectives. Twist offers perfectly clonal genes in
either Twist or customer vectors. For more information please click
here.
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic
biology company that has developed a disruptive DNA synthesis
platform to industrialize the engineering of biology. The core of
the platform is a proprietary technology that pioneers a new method
of manufacturing synthetic DNA by “writing” DNA on a silicon chip.
Twist is leveraging its unique technology to manufacture a broad
range of synthetic DNA-based products, including synthetic genes,
tools for next-generation sequencing (NGS) preparation, and
antibody libraries for drug discovery and development. Twist is
also pursuing longer-term opportunities in digital data storage in
DNA and biologics drug discovery. Twist makes products for use
across many industries including healthcare, industrial chemicals,
agriculture and academic research.
Follow us on Twitter | Facebook | LinkedIn | YouTube
This press release contains forward-looking statements. All
statements other than statements of historical facts contained
herein are forward-looking statements reflecting the current
beliefs and expectations of management made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995, including, but not limited to, Twist Bioscience’s
expectations regarding ability to increase market share and
precisely manufacture scalable quantities of perfect clonal DNA.
Such forward-looking statements involve known and unknown risks,
uncertainties, and other important factors that may cause Twist
Bioscience’s actual results, performance, or achievements to be
materially different from any future results, performance, or
achievements expressed or implied by the forward-looking
statements. Such risks and uncertainties include, among others, the
risks and uncertainties of the ability to attract new customers and
retain and grow sales from existing customers; risks and
uncertainties of rapidly changing technologies and extensive
competition in synthetic biology could make the products Twist
Bioscience is developing obsolete or non-competitive; uncertainties
of the retention of a significant customer; risks of third party
claims alleging infringement of patents and proprietary rights or
seeking to invalidate Twist Bioscience’s patents or proprietary
rights; and the risk that Twist Bioscience’s proprietary rights may
be insufficient to protect its technologies. For a further
description of the risks and uncertainties that could cause actual
results to differ from those expressed in these forward-looking
statements, as well as risks relating to Twist Bioscience’s
business in general, see Twist Bioscience’s risk factors set forth
in Twist Bioscience’s Annual Report on Form 10-K for the year ended
September 30, 2018 filed with the Securities and Exchange
Commission on December 20, 2018. Any forward-looking statements
contained in this press release speak only as of the date hereof,
and Twist Bioscience specifically disclaims any obligation to
update any forward-looking statement, whether as a result of new
information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190107005466/en/
Investor Contact:Argot PartnersMaeve
Conneighton212-600-1902maeve@argotpartners.com
Media Contact:Angela
Bitting925-202-6211media@twistbioscience.com
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Apr 2024 to May 2024
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From May 2023 to May 2024